1.Shionone protects cerebral ischemic injury through alleviating microglia-mediated neuroinflammation.
Lushan XU ; Chenggang LI ; ChenChen ZHAO ; Zibu WANG ; Zhi ZHANG ; Xin SHU ; Xiang CAO ; Shengnan XIA ; Xinyu BAO ; Pengfei SHAO ; Yun XU
Chinese Journal of Natural Medicines (English Ed.) 2025;23(4):471-479
Microglia, the resident immune cells in the central nervous system (CNS), rapidly transition from a resting to an active state in the acute phase of ischemic brain injury. This active state mediates a pro-inflammatory response that can exacerbate the injury. Targeting the pro-inflammatory response of microglia in the semi-dark band during this acute phase may effectively reduce brain injury. Shionone (SH), an active ingredient extracted from the dried roots and rhizomes of the genus Aster (Asteraceae), has been reported to regulate the inflammatory response of macrophages in sepsis-induced acute lung injury. However, its function in post-stroke neuroinflammation, particularly microglia-mediated neuroinflammation, remains uninvestigated. This study found that SH significantly inhibited lipopolysaccharide (LPS)-induced elevation of inflammatory cytokines, including interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and inducible nitric oxide synthase (iNOS), in microglia in vitro. Furthermore, the results demonstrated that SH alleviated infarct volume and improved behavioral performance in middle cerebral artery occlusion (MCAO) mice, which may be attributed to the inhibition of the microglial inflammatory response induced by SH treatment. Mechanistically, SH potently inhibited the phosphorylation of serine-threonine protein kinase B (AKT), mammalian target of rapamycin (mTOR), and signal transducer and activator of transcription 3 (STAT3). These findings suggest that SH may be a potential therapeutic agent for relieving ischemic stroke (IS) by alleviating microglia-associated neuroinflammation.
Animals
;
Microglia/immunology*
;
Mice
;
Male
;
Mice, Inbred C57BL
;
Brain Ischemia/immunology*
;
Neuroinflammatory Diseases/drug therapy*
;
Neuroprotective Agents/administration & dosage*
;
Interleukin-1beta/genetics*
;
STAT3 Transcription Factor/genetics*
;
TOR Serine-Threonine Kinases/genetics*
;
Tumor Necrosis Factor-alpha/genetics*
;
Proto-Oncogene Proteins c-akt/immunology*
;
Nitric Oxide Synthase Type II/genetics*
;
Lipopolysaccharides
2.Compound from Magnolia officinalis Ameliorates White Matter Injury by Promoting Oligodendrocyte Maturation in Chronic Cerebral Ischemia Models.
Zhi ZHANG ; Xin SHU ; Qian CAO ; Lushan XU ; Zibu WANG ; Chenggang LI ; Shengnan XIA ; Pengfei SHAO ; Xinyu BAO ; Liang SUN ; Yuhao XU ; Yun XU
Neuroscience Bulletin 2023;39(10):1497-1511
Chronic cerebral hypoperfusion leads to white matter injury (WMI), which subsequently causes neurodegeneration and even cognitive impairment. However, due to the lack of treatment specifically for WMI, novel recognized and effective therapeutic strategies are urgently needed. In this study, we found that honokiol and magnolol, two compounds derived from Magnolia officinalis, significantly facilitated the differentiation of primary oligodendrocyte precursor cells (OPCs) into mature oligodendrocytes, with a more prominent effect of the former compound. Moreover, our results demonstrated that honokiol treatment improved myelin injury, induced mature oligodendrocyte protein expression, attenuated cognitive decline, promoted oligodendrocyte regeneration, and inhibited astrocytic activation in the bilateral carotid artery stenosis model. Mechanistically, honokiol increased the phosphorylation of serine/threonine kinase (Akt) and mammalian target of rapamycin (mTOR) by activating cannabinoid receptor 1 during OPC differentiation. Collectively, our study indicates that honokiol might serve as a potential treatment for WMI in chronic cerebral ischemia.
Magnolia
;
White Matter
;
Brain Ischemia/metabolism*
;
Oligodendroglia/metabolism*
3.Role of metabolic crosstalk between astrocytes and neurons in ischemic brain injury
Min SUN ; Zibu WANG ; Yun XU ; Yanting CHEN
International Journal of Cerebrovascular Diseases 2023;31(9):703-710
Ischemic stroke is a common cerebrovascular disease with high mortality and disability rates. Astrocytes, as the most abundant glial cells in the brain, have the function of maintaining the homeostasis of the central nervous system, which requires precise coupling between neurotransmission and energy metabolism. Therefore, the metabolic crosstalk between astrocytes and neurons plays an important role in the occurrence and development of ischemic stroke. On the one hand, ischemic stroke leads to neuronal excessive excitation, metabolic disorders, and even death, simultaneously promoting changes in astrocyte metabolism profile and increased heterogeneity. On the other hand, the metabolic crosstalk between astrocytes and neurons can also affect the outcome of ischemic stroke. This article reviews the role of the metabolic crosstalk between astrocytes and neurons in ischemic brain injury, and looks forward to potential research directions and treatment targets in the future, in order to provide theoretical reference for the treatment of ischemic stroke.

Result Analysis
Print
Save
E-mail